

SECURITIES AND EXCHANGE COMMISSION

FORM 10-Q

Quarterly report pursuant to sections 13 or 15(d)

Filing Date: **2023-08-14** | Period of Report: **2023-06-30**  
SEC Accession No. [0001493152-23-028576](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

**GlucoTrack, Inc.**

CIK: **1506983** | IRS No.: **980668934** | State of Incorpor.: **DE** | Fiscal Year End: **1231**  
Type: **10-Q** | Act: **34** | File No.: **001-41141** | Film No.: **231171422**  
SIC: **3841** Surgical & medical instruments & apparatus

Mailing Address

*301 RT 17 NORTH  
SUITE 800  
RUTHERFORD NJ 07070*

Business Address

*301 RT 17 NORTH  
SUITE 800  
RUTHERFORD NJ 07070  
972 (8) 675-7878*

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended June 30, 2023

or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: 001-41141

**GLUCOTRACK, INC.**

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of  
incorporation or organization)

301 Route 17 North, Suite 800  
Rutherford, NJ

(Address of principal executive offices)

98-0668934

(I.R.S. Employer  
Identification No.)

07070

(Zip Code)

(201) 842-7715

(Registrant's telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

**Securities registered pursuant to Section 12(b) of the Act:**

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	GCTK	NASDAQ Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Non-accelerated filer

Emerging growth company

Accelerated filer

Smaller reporting company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of August 11, 2023, 20,892,193 shares of the Company’s common stock, par value \$0.001 per share, were outstanding.

---

---

## GLUCOTRACK INC.

### TABLE OF CONTENTS

	<b>Page</b>
<b><u>PART I - FINANCIAL INFORMATION</u></b>	<b>3</b>
Item 1. Financial Statements.	3
Condensed Consolidated Balance Sheets	3
Condensed Consolidated Statements of Operations and Comprehensive Loss	4
Condensed Consolidated Statement of Changes in Stockholders’ Equity	5
Condensed Consolidated Statements of Cash Flows	6
Notes to Condensed Consolidated Financial Statements	7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.	10
Item 3. Quantitative and Qualitative Disclosures About Market Risk.	14
Item 4. Controls and Procedures.	14
<b><u>PART II - OTHER INFORMATION</u></b>	<b>15</b>
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	15
Item 6. Exhibits.	15
<b><u>EXHIBIT INDEX</u></b>	<b>15</b>
<b><u>SIGNATURES</u></b>	<b>16</b>

## GLUCOTRACK INC.

### PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

## GLUCOTRACK INC.

### CONDENSED CONSOLIDATED BALANCE SHEETS

In thousands of US dollars  
(except share data)

June 30, 2023	December 31, 2022
(Unaudited)	

<b>Current Assets</b>			
Cash and cash equivalents	\$	8,774	\$ 2,312
Other current assets		171	67
Total current assets		<u>8,945</u>	<u>2,379</u>
Property and equipment, net		27	40
Restricted Cash		10	19
<b>TOTAL ASSETS</b>		<u><u>8,982</u></u>	<u><u>2,438</u></u>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>			
<b>Current Liabilities</b>			
Accounts payable		832	672
Other current liabilities		218	341
Total Current Liabilities	\$	1,050	\$ 1,013
<b>Non-current Liabilities</b>			
Loans from Stockholders		189	195
Total Non-current liabilities		<u>189</u>	<u>195</u>
Total Liabilities		1,239	1,208
<b>Stockholders' Equity</b>			
<b>Common Stock of \$ 0.001 par value ("Common Stock"):</b>			
500,000,000 shares authorized as of June 30, 2023 and December 31, 2022;			
20,892,193 and 15,500,730 shares issued and outstanding as of June 30, 2023		20	15
and December 31, 2022, respectively			
Additional paid-in capital		112,918	103,095
Accumulated other comprehensive income		28	17
Receipts on account of shares		-	4
Accumulated deficit		(105,218)	(101,901)
Total Stockholders' equity		<u>7,743</u>	<u>1,230</u>
<b>TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</b>	\$	<u><u>8,982</u></u>	\$ <u><u>2,438</u></u>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**GLUCOTRACK INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**

	<u>US dollars (except share data)</u>		<u>US dollars (except share data)</u>	
	<u>Six-month</u>		<u>Three-month</u>	
	<u>period ended June 30,</u>		<u>period ended June 30,</u>	
	<u>(Unaudited)</u>		<u>(Unaudited)</u>	
	<u>2023</u>	<u>2022</u>	<u>2023</u>	<u>2022</u>
Research and development	\$ 1,269	\$ 929	\$ 627	\$ 469
General and administrative	1,194	1,287	552	654
Total operating expenses	<u>2,463</u>	<u>2,216</u>	<u>1,179</u>	<u>1,123</u>
<b>Operating Loss</b>	2,463	2,216	1,179	1,123

Finance Income (Expenses), net	(1)	4	(3)	4
<b>Net Loss</b>	<u>2,462</u>	<u>2,220</u>	<u>1,176</u>	<u>1,127</u>
Other comprehensive income:				
Foreign currency translation adjustment	(11)	(37)	(6)	(30)
<b>Comprehensive loss for the period</b>	<u>\$ 2,451</u>	<u>\$ (2,183)</u>	<u>\$ 1,170</u>	<u>\$ (1,097)</u>
Basic net loss per common stock	<u>\$ (0.18)</u>	<u>\$ (0.14)</u>	<u>\$ (0.09)</u>	<u>\$ (0.07)</u>
Diluted net loss per common stock	<u>\$ (0.18)</u>	<u>\$ (0.14)</u>	<u>\$ (0.09)</u>	<u>\$ (0.07)</u>
Weighted average number of common shares used in computing basic and diluted loss per common stock	<u>18,532,553</u>	<u>15,465,692</u>	<u>21,561,473</u>	<u>15,473,813</u>

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

## GLUCOTRACK INC.

### CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY

In thousands of US Dollars (except share data)

(Unaudited)

	Common Stock		Additional Paid-in Capital	Receipts on account of shares	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Total Stockholders' Equity
	Numbers of Shares	Amount					
<b>Balance at January 1, 2023</b>	15,550,730	\$ 15	\$ 103,095	\$ 4	\$ 17	\$ (101,901)	\$ 1,230
Loss for the period	-	-	-	-	-	(2,462)	(2,462)
Other comprehensive income	-	-	-	-	11	-	11
Deemed dividend resulted from trigger of down round protection feature of certain warrants granted	-	-	855	-	-	(855)	-
Issuance of Ordinary Shares upon completion of public offering, net of offering expenses	5,376,472	5	8,725	-	-	-	8,730
Issuance of restricted shares as compensation towards directors and officer	14,991	-(*)	9	(4)	-	-	5
Stock-based compensation	-	-	229	-	-	-	229
<b>Balance at June 30, 2023</b>	<u>20,892,193</u>	<u>\$ 20</u>	<u>\$ 112,913</u>	<u>\$ -</u>	<u>\$ 28</u>	<u>\$ (105,218)</u>	<u>\$ 7,743</u>
<b>Balance at April 1, 2023</b>	15,503,632	\$ 15	\$ 103,156	\$ 5	\$ 22	\$ (103,187)	\$ 11
Loss for the period	-	-	-	-	-	(1,176)	(1,176)
Other comprehensive income	-	-	-	-	6	-	6
Deemed dividend resulted from trigger of down round protection	-	-	855	-	-	(855)	-

feature of certain warrants granted								
Issuance of Ordinary Shares upon completion of public offering, net of offering expenses	5,376,472	5	8,725	-	-	-	-	8,730
Issuance of restricted shares as compensation towards directors and officer	12,089	-(*)	5	(5)	-	-	-	-
Stock-based compensation	-	-	172	-	-	-	-	172
<b>Balance at June 30, 2023</b>	<u>20,892,193</u>	<u>\$ 20</u>	<u>\$ 112,913</u>	<u>\$ -</u>	<u>\$ 28</u>	<u>\$ (105,218)</u>	<u>\$ 7,743</u>	
<b>Balance at January 1, 2022</b>	15,452,285	\$ 15	\$ 102,612	\$ -	\$ (6)	\$ (97,466)	\$ 5,155	
Loss for the period						(2,220)	(2,220)	
Other comprehensive income	-	-	-	-	37	-	37	
Issuance of restricted shares as compensation towards directors (**)	7,872	-(*)	11	9	-	-	20	
Stock-based compensation	13,105	-	198	-	-	-	198	
<b>Balance at June 30, 2022</b>	<u>15,473,262</u>	<u>\$ 15</u>	<u>\$ 102,821</u>	<u>\$ 9</u>	<u>\$ 31</u>	<u>\$ (99,686)</u>	<u>\$ 3,190</u>	
<b>Balance at April 1, 2022</b>	15,452,285	\$ 15	\$ 102,763	\$ 11	\$ 1	\$ (98,559)	\$ 4,231	
Loss for the period	-	-	-	-	-	(1,127)	(1,127)	
Other comprehensive income	-	-	-	-	30	-	30	
Issuance of restricted shares as compensation towards directors (**)	7,872	-(*)	11	(2)	-	-	9	
Stock-based compensation	13,105	-(*)	47	-	-	-	47	
<b>Balance at June 30, 2022</b>	<u>15,473,262</u>	<u>\$ 15</u>	<u>\$ 102,821</u>	<u>\$ 9</u>	<u>\$ 31</u>	<u>\$ (99,686)</u>	<u>\$ 3,190</u>	

(\*) Represents amount lower than \$1.

(\*\*) Actual issuance occurred subsequent to the balance sheet date.

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

## GLUCOTRACK INC.

### CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	US Dollars	
	Six-month period ended June 30.	
	2023	2022
	(Unaudited)	
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Loss for the period	\$ (2,462)	\$ (2,220)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation	7	14
Stock-based compensation	229	198
Issuance of restricted shares as compensation towards directors	5	20(*)
Linkage difference on principal of loans from stockholders	6	6
<b>Changes in assets and liabilities:</b>		
Increase in other current assets	(104)	(331)

Increase in accounts payable	173	18
Increase (Decrease) in other current liabilities	(121)	114
<b>Net cash used in operating activities</b>	<b>(2,267)</b>	<b>(2,181)</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Purchase of property and equipment	-	(4)
<b>Net cash used in investing activities</b>	<b>-</b>	<b>(4)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Net proceeds received from underwritten U.S. public offering	8,730	-
<b>Net cash provided by financing activities</b>	<b>8,730</b>	<b>-</b>
Effect of exchange rate changes on cash and cash equivalents, and restricted cash	(10)	(30)
Change in cash, cash equivalents, and restricted cash	6,453	(2,215)
Cash, cash equivalents, and restricted cash at beginning of the period	2,331	6,113
Cash, cash equivalents, and restricted cash, end of period	<u>\$ 8,784</u>	<u>\$ 3,898</u>
<b>Non-cash financing activities</b>		
Deemed dividend upon trigger of down round protection	<u>\$ 855</u>	<u>\$ -</u>

(\* ) Actual issuance occurred subsequent to the balance sheet date.

**The accompanying notes are an integral part of these condensed consolidated financial statements.**

## GLUCOTRACK INC.

### NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

#### NOTE 1 – GENERAL

A. GlucoTrack Inc. (the “Company”) was incorporated on May 18, 2010 under the laws of the State of Delaware. The Company is a medical device company, focused on the design, development and commercialization of novel technologies for use by people with diabetes and prediabetes. The Company is currently developing two products; a non-invasive glucose monitor for use by persons with Type 2 diabetes and prediabetes, and an implantable continuous glucose monitor for persons with Type 1 diabetes and insulin-dependent Type 2 diabetes.

#### B. Liquidity and Going Concern Uncertainty

To date, the Company has not yet generated significant revenues from selling of GlucoTrack 1.0 product, a product that has been discontinued. In addition, development and commercialization of both GlucoTrack 2.0 product and the implantable continuous glucose monitor is expected to require substantial expenditures; therefore, the Company is dependent upon external sources for financing its operations. As of June 30, 2023, the Company has incurred accumulated deficit of \$105,218 thousand. Furthermore, the Company has generated operating losses and negative operating cash flow for all reported periods.

Management has considered the significance of such conditions in relation to the Company’s ability to meet its current obligations and to achieve its business targets and determined that these conditions do not raise substantial doubt about the Company’s ability to continue as a going concern, taking into consideration the net proceeds received in total amount of \$8,730 thousand upon closing of a public offering through prospectus supplement on Form S-3 on April 17 2023 (see also Note 3

below). Based on its assessment, management believe that such funds are sufficient for the Company to realize its business plans for the twelve months subsequent to the reporting period.

## NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

### A. Basic of Presentation

#### 1. Accounting Principles

The accompanying unaudited condensed consolidated interim financial statements and related notes should be read in conjunction with the consolidated financial statements and related notes contained in the Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2023. The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature.

The results for the period of six months ended June 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other interim period or for any future period.

#### 2. Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany balances and transactions have been eliminated in consolidation.

7

---

## GLUCOTRACK INC.

### NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

## NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)

### A. Basic of Presentation

#### 3. Net Loss Per Common Stock

Basic net loss per Common Stock is computed by dividing the loss for the period applicable for holders of Common Stock and pre-funded warrants by the weighted average number of shares of Common Stock and pre-funded warrants outstanding during the period. Diluted loss per share gives effect to all potentially dilutive common shares outstanding during the period using the treasury stock method with respect to stock options and certain stock warrants. In computing diluted loss per Common Stock, the average stock price for the period is used in determining the number of Common Stock assumed to be purchased from the exercise of stock options or stock warrants.

Shares to be issued upon exercise of all stock options and stock warrants have been excluded from the calculation of the diluted net loss per Common Stock for all the reported periods for which net loss was reported because the effect of the Common Stock issuable upon exercise of these instruments was anti-dilutive.

The net loss and the weighted average number of shares of Common Stock used in computing basic and diluted net loss per Common Stock for the period of six and three months ended June 30, 2023 and 2022, is as follows:

<u>US dollars (except share data)</u>	<u>US dollars (except share data)</u>
<u>Six-month period ended June 30,</u>	<u>Three-month period ended June 30,</u>

	(Unaudited)		(Unaudited)	
	2023	2022	2023	2022
<b>Numerator:</b>				
Net loss	\$ 2,462	\$ 2,220	\$ 1,176	\$ 1,127
Deemed dividend related to trigger of down round protection feature (see Note 3A below)	855	-	855	-
Net loss attributable to common stockholders	\$ 3,317	\$ 2,220	\$ 2,031	\$ 1,127
<b>Denominator:</b>				
Ordinary shares used in computing basic and diluted net loss per common stock	(* )18,532,553	15,465,692	(* )21,561,473	15,473,813
Basic and diluted net loss per common stock	\$ (0.19)	\$ (0.14)	\$ (0.10)	\$ (0.07)

(\*) Including pre-funded warrants issued upon completion of underwritten U.S. public offering.

## GLUCOTRACK INC.

### NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONT.)

#### NOTE 3 - SIGNIFICANT TRANSACTIONS

##### A. Completion of underwritten U.S. public offering

On April 13, 2023, the Company completed an underwritten public offering under which the Company received gross proceeds of approximately \$10,000 thousand for issuance of (i) 5,376,472 shares of common stock and (ii) 1,976,470 pre-funded warrants at a price to the public of \$1.36 per share. The pre-funded warrants are exercisable for the same number of shares of common stock and may be exercised at any time until exercised in full at an exercise price of \$0.001.

Upon satisfaction of customary closing conditions, the closing date of the above underwritten public offering was April 17, 2023 (the "Closing Date").

The Company received substantially all the pre-funded warrant's proceeds upfront (without any conditions) as part of the pre-funded warrant's purchase price and in return the Company is obligated to issue fixed number of shares of common stock to the holders. Thus, pre-funded warrants were accounted for and were classified as additional paid-in capital as part of the Company's stockholders' equity.

Total incremental and direct issuance costs amounted to \$1,270 thousand. These expenses were deducted from additional paid-in capital as they were allocated to shares of Common Stock and pre-funded warrants.

Upon closing of underwritten U.S. public offering, a down round protection feature of certain warrants granted in previous years to service providers was triggered by the way of reduction of their exercise price from a price in a range of \$3.35-\$70.20 to a price of \$1.36 which represented the above public offering price. Such reduction was accounted for as deemed dividend estimated at total amount of \$855 thousand which was recorded as part of the additional paid-in capital versus increase of accumulated deficit. Regarding the effect of the loss per share, see also Note 2.A.3. above.

##### B. Intellectual Property Purchase Agreement

In the middle of June 2023, the Company achieved the first performance milestone out of the five performance milestones outlined in the Intellectual Property Purchase Agreement (the "Agreement") executed between the Company and Paul Goode,

which is the Company's Chief Executive Officer (the "Seller") as October 7, 2022 (the "Closing Date"). As result, the Company is committed to issue 100,000 restricted shares to the Seller. During the periods of three and six months ended June 30, 2023, the Company recorded stock-based compensation expenses amounted to \$131 thousand which representing the quoted price of its Common Stock at the Closing Date, after taking into consideration a discount for lack of marketability in a rate of 30.4% over a restriction period of 1-year. As of June 30, 2023, achievement of all other performance milestones was not considered probable and thus no stock-based compensation expenses were recorded with respect to thereof.

### C. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

On May 26, 2023, the Company received a letter from Nasdaq that it no longer complies with Rule 5550(a)(2) of Nasdaq's Listing Rules (the "Rules") which require listed securities to maintain a minimum bid price of \$1 per share. However, the Rules provide the Company a compliance period of 180-days to regain compliance under which if at any time during 180-days period the closing bid price of the Company's security is at least \$1 for a minimum of ten consecutive business days, Nasdaq will provide the Company written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance by the 180th day, the Company may be eligible for additional time to regain compliance or may face delisting.

### NOTE 4 - SUBSEQUENT EVENTS

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed interim consolidated financial statements were issued (August 14, 2023). Based upon this review, the Company did not identify any other subsequent events that would have required adjustment or disclosure in the financial statements.

## Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

### Cautionary Note Regarding Forward-Looking Statements

*This Quarterly Report on Form 10-Q contains forward-looking statements. These forward-looking statements include statements about our expectations, beliefs or intentions regarding our product development efforts, business, financial condition, results of operations, strategies and prospects. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q, including statements regarding our future activities, events or developments, including such things as future revenues, capital raising and financing, product development, clinical trials, regulatory approval, market acceptance, responses from competitors, capital expenditures (including the amount and nature thereof), business strategy and measures to implement strategy, competitive strengths, goals, expansion and growth of our business and operations, plans, references to future success, projected performance and trends, and other such matters, are forward-looking statements. The words "believe," "expect," "anticipate," "intend," "estimate," "plan," "may," "will," "could," "would," "should" and other similar words and phrases, are intended to identify forward-looking statements. The forward-looking statements made in this Quarterly Report on Form 10-Q are based on certain historical trends, current conditions and expected future developments as well as other factors we believe are appropriate in the circumstances. These statements relate only to events as of the date on which the statements are made and we undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this Quarterly Report on Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Whether actual results will conform to our expectations and predictions is subject to a number of risks and uncertainties that may cause actual results to differ materially. Risks and uncertainties, the occurrence of which could adversely affect our business, include the risks identified under the caption "Risk Factors" included in our annual report on Form 10-K for the year ended December 31, 2022. The following discussion should be read in conjunction with the condensed consolidated financial statements and the notes thereto included in Item 1 of this Quarterly Report on Form 10-Q.*

### Overview

We are a medical device company focused on the design, development and commercialization of novel technologies for use by people with diabetes and prediabetes. We are currently developing two products; a non-invasive glucose monitor for use by those with Type 2 diabetes and prediabetes, and an implantable continuous glucose monitor for those with Type 1 diabetes and insulin-dependent Type 2 diabetes.

The Company was founded with a mission to develop GlucoTrack®, a noninvasive glucose monitoring device designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive) spot finger stick devices. The first generation GlucoTrack (“GlucoTrack 1.0”), which successfully received CE Mark approval and ISO certifications, utilized a combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in approximately one minute via a small sensor that is clipped onto one’s earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. After a limited release beta test in Europe and the Middle East, the Company determined that it would focus its efforts on developing its next generation non-invasive monitor (“GlucoTrack 2.0”), and we have since withdrawn our CE Mark and ISO certifications for GlucoTrack 1.0 and are no longer pursuing commercialization of this product.

Instead, we are currently developing GlucoTrack 2.0. The current clinical prototype utilizes ultrasound-only sensor technology, reduces the overall cost and complexity of the device, and reduces the measurement time from approximately sixty seconds to less than two seconds. Initial testing has produced promising results, suggesting measurement accuracies could be relatively comparable with those of conventional, already in-the-market CGM technologies. Internal development efforts continue toward a robust measurement technique that consistently achieves significant measurement accuracy in normal use applications. A first-in-human (FIH) clinical study will begin once this metric has been achieved.. Collecting data for sensor characterization and algorithm development will be the primary goals of the FIH study. The results of this study will also drive the development of the commercial version of the device, which is expected to commence early 2024. Once the development of the commercial device version is complete, we intend to conduct a scaled down version of the FDA pivotal trial to resolve any lingering device performance or human factors issues prior to executing the larger pivotal trial for FDA submission.

Following the acquisition of certain IP in the fourth quarter of 2022, we are also developing an implantable continuous glucose monitor for use by Type 1 diabetes patients as well as insulin-dependent Type 2 patients. Implant longevity is key to the success of such a device, and we have recently completed our feasibility study successfully demonstrating that a minimum two-year implant life is highly probable with the current sensor design. We believe our technology, if successful, has the potential to be more accurate, more convenient and have a longer duration than other implantable glucose monitors that are either in the market or currently under development.

We are currently developing our own companion applications and a cloud-based solutions to offer an effective platform to provide real time, data driven personalized tools to effectively help a user manage their diabetes, which will be utilized during the clinical trials. In addition to being a critical and effective management tool for the end user, we believe that third parties such as insurers, pharmaceutical companies and advertisers would be willing to pay for the de-identified data that we will obtain through our platform, and that this is an opportunity for us to develop an additional revenue source.

Our Senior Management team includes; CEO and President, Paul V. Goode PhD, who has a decorated career developing innovative medical technologies, including at DexCom and MiniMed, CFO and General Counsel, Jolie Kahn, Esq., who has a multidecade career as a well respected securities attorney and finance professional, James P. Thrower PhD, Vice President of Engineering, a seasoned executive formerly of Sterling Medical Devices, Mindray DS USA and DexCom, Inc., and Mark Tapsak PhD, Vice President of Sensor Technology, a medical research scientist who brings over 25 years of experience in the diabetes industry, including previous senior roles at DexCom and Medtronic. Luis J. Malavé, formerly of Insulet Corp, Medtronic and MiniMed has joined as an independent board member. Several highly talented and accomplished executives joined the Company as senior advisors to the Board. These include Yair Briman, the former CEO of Philips Healthcare Informatics, Daniel McCaffrey MBA MA, a world-renowned behavioral scientist and digital health expert formerly at Samsung Health and Dexcom, Inc., Dr. Alexander Raykhman PhD, a measurement and artificial intelligence expert and Dr. David C. Klonoff, world renowned endocrinologist and diabetes technology thought leader. We intend to continue to invest in our talent and to expand and strengthen all areas within the Company.

## **Recent Events**

On March 14, 2022, we changed our name to GlucoTrack, Inc. and our trading symbol to GCTK.

On March 22, 2022, Shalom Shushan, Chief Technology Officer, provided notice of his resignation from the Company, effective May 22, 2022, for personal reasons. In connection with the Company’s previously announced plans to migrate certain aspects of product development to the United States, James P. Thrower PhD, Vice President of Engineering, assumed Mr. Shushan’s responsibilities.

In connection with the Company’s previously announced plans to migrate certain aspects of the product development to the United States, as well as in preparation for U.S. clinical trials, Erez Ben-Zvi, VP of Product in Israel, resigned from the Company, effective June 12, 2022.

On October 10, 2022, the Company announced that it has acquired certain IP related to a long-term implantable continuous glucose monitor and that it intends to develop the technology to address the growing Type 1 and insulin dependent Type 2 diabetes market.

On October 14, 2022, the Company announced the hiring of Dr. Mark Tapsak as Vice President of Sensor Technology.

On November 22, 2022, Nasdaq provided notice that pursuant to Nasdaq Listing Rule 5550(b)(1), the Company did not meet the alternatives of market value of listed securities or net income from continuing operations.

On January 4, 2023, Nasdaq provided notice that since the Company had not held an annual meeting of shareholders within twelve months of the end of the Company's fiscal year ended December 31, 2021, it no longer complied with Listing Rules for continued listing.

On February 7, 2023, Nasdaq issued a letter to the Company granting an extension until May 22, 2023 to obtain compliance with the Listing Rule 5550(b).

On March 31, 2023, GlucoTrack, Inc. held its 2022 Annual Meeting of Shareholders. The results of the voting with respect to this Annual Meeting are as set forth below.

#### Directors Information

Dir #	Votes For	Votes Withheld	Broker Non-Vote	% Votes For
Dr. Robert Fischell	2,881,036.00	5,250,502.00	488,583.00	18.58
Luis Malave	2,880,918.00	5,250,620.00	488,583.00	18.58
Andrew Sycoff	2,945,847.00	5,185,691.00	488,583.00	19.00
Shimon Rapps	2,882,073.00	5,249,465.00	488,583.00	18.59
Allen Danzig	2,880,916.00	5,250,622.00	488,583.00	18.58

#### Proposals Information

Prop #	Votes For	Votes Against	Votes Abstain	Broker Non-Vote	% Votes For
Ratify Auditor	8,612,584.00	7,481.00	56.00	0.00	55.55
Nonbinding Say on Pay	2,844,095.00	5,205,181.00	82,262.00	488,583.00	18.34

On April 17, 2023, the Company announced the closing of a firm commitment underwritten public offering of shares of its common stock with gross proceeds to the Company of approximately \$10 million, before deducting underwriting discounts and other estimated expenses. The offering consisted of 5,376,472 shares of common stock and 1,976,470 pre-funded warrants to purchase shares of common stock at a price to the public of \$1.36 per share (less \$0.001 in exercise price per pre-funded warrant). The Company entered into an underwriting agreement with Aegis Capital Corp. on April 13, 2023. The Company intends to use the net proceeds from this offering primarily for working capital and general corporate purposes, which may include, without limitation, engaging in acquisitions or other business combinations or investments, sales and marketing activities, general and administrative matters and capital expenditures.

On July 25, 2023, the Company announced the completion and positive results of its feasibility study for its implantable continuous glucose monitor technology for patients with Type 1 and Type 2 insulin-dependent diabetes. The primary goal of the feasibility study was to demonstrate that the CGM sensor design could reliably report glucose measurements for two years post-implant. Laboratory bench testing confirmed that a minimum two-year implant longevity is highly probable with the current sensor design. The implant longevity was independently verified by a third-party using sensor parameters to simulate sensor performance over time. Given the positive results of the study, the Company is now preparing for long-term animal studies, which are expected to begin later this year.

The summary of our significant accounting policies is included under Item 7 – Management's Discussion and Analysis of Financial Condition and Results of Operations of our fiscal 2022 Form 10-K. An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably possible could materially impact the financial statements. There have been no material changes to the critical accounting policies and estimates as filed in such report.

## Critical Accounting Policies

This Management's Discussion and Analysis of Financial Condition and Results of Operations discuss our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). In connection with the preparation of our financial statements, we are required to make assumptions and estimates about future events and apply judgments that affect the reported amounts of assets, liabilities, expenses and the related disclosures. We base our assumptions, estimates and judgments on historical experience, current trends and other factors that management believes to be relevant at the time our consolidated financial statements are prepared. On a regular basis, management reviews the accounting policies, assumptions, estimates and judgments to ensure that our financial statements are presented fairly and in accordance with U.S. GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material.

## Results of Operations

The following discussion of our operating results explains material changes in our results of operations for the six month period ended June 30, 2023 compared with the same period ended June 30, 2022. The discussion should be read in conjunction with the financial statements and related notes included elsewhere in this report.

### Six Months ended June 30, 2023 compared to Six Months ended June 30, 2022

#### Research and development expenses

Research and development expenses were \$1,269 thousand for the six-month period ended June 30, 2023, as compared to \$929 thousand for the prior-year period. The increase is attributable to professional fees we accrued during the period.

Research and development expenses consist primarily of salaries and other personnel-related expenses, materials, clinical trials and other expenses. We expect research and development expenses to increase in 2023 and beyond, primarily due to hiring additional personnel and developing and validating our next generation product line, however, we may adjust or allocate the level of our research and development expenses based on available financial resources and based on our commercial needs, including the FDA registration process, specific requirements from customers, development of new GlucoTrack® models and others.

#### General and administrative expenses

General and administrative expenses were \$1,194 thousand for the six-month period ended June 30, 2023, as compared to \$1,287 thousand for the prior-year period. The decrease is attributable to professional fees we accrued during the period.

General and administrative expenses consist primarily of professional services, salaries, consulting fees, insurance, travel expenses and other related expenses for executive, finance and administrative personnel, including stock-based compensation expenses. Other general and administrative costs and expenses include facility-related costs not otherwise included in research and development costs and expenses, and professional fees for legal and accounting services.

#### Financing income (expenses), net

Financing expenses, net was approximately \$1 thousand for the six-month period ended June 30, 2023, as compared to financing income of \$4 thousand for the prior-year period. The change is immaterial.

#### Net Loss

Net loss was \$2,462 thousand for the six-month period ended June 30, 2023, as compared to \$2,220 thousand for the prior-year period. The increase in net loss is attributable primarily to the increase in our operating expenses, as described above.

## Going Concern Uncertainty

The development and commercialization of GlucoTrack 2.0 product are expected to require substantial further expenditures. We remain dependent upon external sources for financing our operations. Since inception, we have incurred substantial accumulated losses and negative operating cash flow and have a significant accumulated deficit. However, in April 2023, we completed an underwriting U.S. public offering under which net proceeds of \$8,730 thousand has been raised. As of June 30, 2023, our cash on hand is sufficient to continue our operations for a period of twelve-months subsequent to the reporting period.

### *Net Cash Used in Operating Activities for the Six-Month Periods Ended June 30, 2023 and June 30, 2022*

Net cash used in operating activities was \$2,269 thousand and \$2,181 thousand for the six-month periods ended June 31, 2023 and 2022, respectively. Net cash used in operating activities primarily reflects the net loss for those periods of \$2,462 thousand and \$2,220 thousand, respectively.

### *Net Cash Used in Investing Activities for the Six-Month Periods Ended June 30, 2023 and June 30, 2022*

Net cash used in investing activities was \$0 thousand and \$4 thousand for the six-month periods ended June 30, 2023 and 2022, respectively. Net cash used in investing activities primarily reflects the purchasing of fixed assets.

### *Net Cash Used in Financing Activities for the Six-Month Periods Ended June 30, 2023 and June 30, 2022*

Net cash provided by financing activities was \$8,730 thousand and \$0 thousand for the six-month periods ended June 30, 2023 and 2022, respectively. Net cash provided by financing activities primarily reflects the net proceeds received from public offering, net of offering expenses.

## Off-Balance Sheet Arrangements

As of June 30, 2023, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.

## Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not required for smaller reporting companies.

## Item 4. Controls and Procedures.

### *Evaluation of Disclosure Controls and Procedures*

Our management, with the participation of our Principal Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of June 30, 2023, or the Evaluation Date. Based on such evaluation, those officers have concluded that, as of the Evaluation Date, our disclosure controls and procedures are ineffective in recording, processing, summarizing and reporting, on a timely basis, information required to be included in periodic filings under the Exchange Act and that such information is not accumulated and communicated to management, including our principal executive and financial officers, in a manner sufficient to allow timely decisions regarding required disclosure, due to the material weaknesses in internal control over financial reporting related to lack of sufficient internal accounting personnel, segregation of duties, and lack of sufficient internal controls (including IT general controls) that encompass the Company as a whole with respect to entity and transactions level controls in order to ensure complete documentation of complex and non-routine transactions and adequate financial reporting.

Management has identified corrective actions to remediate such material weaknesses, which includes hiring additional employees. Management intends to implement procedures to remediate such material weaknesses during the fiscal year 2023; however, the implementation of these initiatives may not fully address any material weaknesses that we may have in our internal control over financial reporting.

### *Changes in Internal Control over Financial Reporting*

There were no changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## PART II - OTHER INFORMATION

### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

*None*

### Item 3. Defaults Upon Senior Securities

*None*

### Item 4. Mine Safety Disclosures

*None*

### Item 6. Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
31.1	<a href="#">Certification of Principal Executive Officer and Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a>
32.1	<a href="#">Certification of Principal Executive Officer and Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a>
101.INS	Inline XBRL Instance Document
101.SCH	Inline XBRL Schema Document
101.CAL	Inline XBRL Calculation Linkbase Document
101.LAB	Inline XBRL Label Linkbase Document
101.PRE	Inline XBRL Presentation Linkbase Document
101.DEF	Inline XBRL Definition Linkbase Document
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

15

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: August 14, 2023

GLUCOTRACK, INC.

By: /s/ Jolie Kahn

Name: Jolie Kahn

Title Chief Financial Officer  
(Principal Financial Officer)

16

**CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF  
THE SECURITIES EXCHANGE ACT OF 1934,  
AS ADOPTED PURSUANT TO SECTION 302 OF  
THE SARBANES-OXLEY ACT OF 2002**

I, Paul Goode, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2023 of GlucoTrack, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 14, 2023

By: /s/ Paul Goode

Paul Goode  
Principal Executive Officer

**CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF  
THE SECURITIES EXCHANGE ACT OF 1934,  
AS ADOPTED PURSUANT TO SECTION 302 OF  
THE SARBANES-OXLEY ACT OF 2002**

I, Jolie Kahn, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2023 of GlucoTrack, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 14, 2023

By: /s/ Jolie Kahn

Jolie Kahn  
Principal Financial Officer

**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of GlucoTrack, Inc. (the "Company") for the period ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Paul Goode, Principal Executive Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

- (1) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By: /s/ Paul Goode

Paul Goode  
Principal Executive Officer

Dated: August 14, 2023

---

**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of GlucoTrack, Inc. (the "Company") for the period ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Jolie Kahn, Principal Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

- (1) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By: /s/ Jolie Kahn

Jolie Kahn  
Principal Financial Officer

Dated: August 14, 2023

---

Cover - shares

6 Months Ended

Jun. 30, 2023

Aug. 11, 2023

[Cover \[Abstract\]](#)

<a href="#">Document Type</a>	10-Q	
<a href="#">Amendment Flag</a>	false	
<a href="#">Document Quarterly Report</a>	true	
<a href="#">Document Transition Report</a>	false	
<a href="#">Document Period End Date</a>	Jun. 30, 2023	
<a href="#">Document Fiscal Period Focus</a>	Q2	
<a href="#">Document Fiscal Year Focus</a>	2023	
<a href="#">Current Fiscal Year End Date</a>	--12-31	
<a href="#">Entity File Number</a>	001-41141	
<a href="#">Entity Registrant Name</a>	GLUCOTRACK, INC.	
<a href="#">Entity Central Index Key</a>	0001506983	
<a href="#">Entity Tax Identification Number</a>	98-0668934	
<a href="#">Entity Incorporation, State or Country Code</a>	DE	
<a href="#">Entity Address, Address Line One</a>	301 Route 17 North	
<a href="#">Entity Address, Address Line Two</a>	Suite 800	
<a href="#">Entity Address, City or Town</a>	Rutherford	
<a href="#">Entity Address, State or Province</a>	NJ	
<a href="#">Entity Address, Postal Zip Code</a>	07070	
<a href="#">City Area Code</a>	(201)	
<a href="#">Local Phone Number</a>	842-7715	
<a href="#">Title of 12(b) Security</a>	Common Stock	
<a href="#">Trading Symbol</a>	GCTK	
<a href="#">Security Exchange Name</a>	NASDAQ	
<a href="#">Entity Current Reporting Status</a>	Yes	
<a href="#">Entity Interactive Data Current</a>	Yes	
<a href="#">Entity Filer Category</a>	Non-accelerated Filer	
<a href="#">Entity Small Business</a>	true	
<a href="#">Entity Emerging Growth Company</a>	false	
<a href="#">Entity Shell Company</a>	false	
<a href="#">Entity Common Stock, Shares Outstanding</a>		20,892,193

**Condensed Consolidated  
Balance Sheets - USD (\$)  
\$ in Thousands**

	<b>Jun. 30, 2023</b>	<b>Dec. 31, 2022</b>
<b><u>Current Assets</u></b>		
<u>Cash and cash equivalents</u>	\$ 8,774	\$ 2,312
<u>Other current assets</u>	171	67
<u>Total current assets</u>	8,945	2,379
<u>Property and equipment, net</u>	27	40
<u>Restricted Cash</u>	10	19
<b><u>TOTAL ASSETS</u></b>	<b>8,982</b>	<b>2,438</b>
<b><u>Current Liabilities</u></b>		
<u>Accounts payable</u>	832	672
<u>Other current liabilities</u>	218	341
<u>Total Current Liabilities</u>	1,050	1,013
<b><u>Non-current Liabilities</u></b>		
<u>Loans from Stockholders</u>	189	195
<u>Total Non-current liabilities</u>	189	195
<u>Total Liabilities</u>	1,239	1,208
<b><u>Stockholders' Equity</u></b>		
<u>Common Stock of \$ 0.001 par value ("Common Stock") : 500,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 20,892,193 and 15,500,730 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively</u>	20	15
<u>Additional paid-in capital</u>	112,918	103,095
<u>Accumulated other comprehensive income</u>	28	17
<u>Receipts on account of shares</u>		4
<u>Accumulated deficit</u>	(105,218)	(101,901)
<u>Total Stockholders' equity</u>	7,743	1,230
<b><u>TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</u></b>	<b>\$ 8,982</b>	<b>\$ 2,438</b>

**Condensed Consolidated  
Balance Sheets  
(Parenthetical) - \$ / shares**

**Jun. 30, 2023 Dec. 31, 2022**

**Statement of Financial Position [Abstract]**

<u>Common stock, par value</u>	\$ 0.001	\$ 0.001
<u>Common stock, shares authorized</u>	500,000,000	500,000,000
<u>Common stock, shares issued</u>	20,892,193	15,500,730
<u>Common stock, shares outstanding</u>	20,892,193	15,500,730

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD (\$) \$ in Thousands	3 Months Ended		6 Months Ended	
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
<b><u>Income Statement [Abstract]</u></b>				
<u>Research and development</u>	\$ 627	\$ 469	\$ 1,269	\$ 929
<u>General and administrative</u>	552	654	1,194	1,287
<u>Total operating expenses</u>	1,179	1,123	2,463	2,216
<u>Operating Loss</u>	1,179	1,123	2,463	2,216
<u>Finance Income (Expenses), net</u>	(3)	4	(1)	4
<u>Net Loss</u>	1,176	1,127	2,462	2,220
<b><u>Other comprehensive income:</u></b>				
<u>Foreign currency translation adjustment</u>	(6)	(30)	(11)	(37)
<u>Comprehensive loss for the period</u>	\$ 1,170	\$ (1,097)	\$ 2,451	\$ (2,183)
<u>Basic net loss per common stock</u>	\$ (0.09)	\$ (0.07)	\$ (0.18)	\$ (0.14)
<u>Diluted net loss per common stock</u>	\$ (0.09)	\$ (0.07)	\$ (0.18)	\$ (0.14)
<u>Weighted average number of common stock outstanding used in computing basic net loss per share</u>	21,561,473	15,473,813	18,532,553	15,465,692
<u>Weighted average number of common stock outstanding used in computing diluted net loss per share</u>	21,561,473	15,473,813	18,532,553	15,465,692

<b>Condensed Consolidated Statement of Changes In Stockholders' Equity (Unaudited) - USD (\$) \$ in Thousands</b>	<b>Common Stock [Member]</b>	<b>Additional Paid-in Capital [Member]</b>	<b>Receipts on Account of Shares [Member]</b>	<b>AOCI Attributable to Parent [Member]</b>	<b>Retained Earnings [Member]</b>	<b>Total</b>
<u>Beginning balance at Dec. 31, 2021</u>	\$ 15	\$ 102,612		\$ (6)	\$ (97,466)	\$ 5,155
<u>Beginning balance, shares at Dec. 31, 2021</u>	15,452,285					
<u>Loss for the period</u>					(2,220)	(2,220)
<u>Other comprehensive income</u>				37		37
<u>Issuance of restricted shares as compensation towards directors</u>	[1]	11	9			20
<u>Issuance of restricted shares as compensation towards directors, shares</u>	[2] 7,872					
<u>Stock-based compensation</u>		198				198
<u>Stock-based compensation, shares</u>	[2] 13,105					
<u>Ending balance at Jun. 30, 2022</u>	\$ 15	102,821	9	31	(99,686)	3,190
<u>Ending balance, shares at Jun. 30, 2022</u>	15,473,262					
<u>Beginning balance at Mar. 31, 2022</u>	\$ 15	102,763	11	1	(98,559)	4,231
<u>Beginning balance, shares at Mar. 31, 2022</u>	15,452,285					
<u>Loss for the period</u>					(1,127)	(1,127)
<u>Other comprehensive income</u>				30		30
<u>Issuance of restricted shares as compensation towards directors</u>	[1]	11	(2)			9
<u>Issuance of restricted shares as compensation towards directors, shares</u>	[2] 7,872					
<u>Stock-based compensation</u>		47				47
<u>Stock-based compensation, shares</u>	[2] 13,105					
<u>Ending balance at Jun. 30, 2022</u>	\$ 15	102,821	9	31	(99,686)	3,190
<u>Ending balance, shares at Jun. 30, 2022</u>	15,473,262					
<u>Beginning balance at Dec. 31, 2022</u>	\$ 15	103,095	4	17	(101,901)	1,230
<u>Beginning balance, shares at Dec. 31, 2022</u>	15,550,730					
<u>Loss for the period</u>					(2,462)	(2,462)
<u>Other comprehensive income</u>				11		11

<u>Deemed dividend resulted from trigger of down round protection feature of certain warrants granted</u>		855			(855)	
<u>Issuance of Ordinary Shares upon completion of public offering, net of offering expenses</u>	\$ 5	8,725				8,730
<u>Issuance of Ordinary Shares upon completion of public offering, net of offering expenses, shares</u>	[2] 5,376,472					
<u>Issuance of restricted shares as compensation towards directors</u>		9	(4)			5
<u>Issuance of restricted shares as compensation towards directors, shares</u>	[2] 14,991					
<u>Stock-based compensation</u>		229				229
<u>Ending balance at Jun. 30, 2023</u>	\$ 20	112,913		28	(105,218)	7,743
<u>Ending balance, shares at Jun. 30, 2023</u>		20,892,193				
<u>Beginning balance at Mar. 31, 2023</u>	\$ 15	103,156	5	22	(103,187)	11
<u>Beginning balance, shares at Mar. 31, 2023</u>		15,503,632				
<u>Loss for the period</u>					(1,176)	(1,176)
<u>Other comprehensive income</u>				6		6
<u>Deemed dividend resulted from trigger of down round protection feature of certain warrants granted</u>		855			(855)	
<u>Issuance of Ordinary Shares upon completion of public offering, net of offering expenses</u>	\$ 5	8,725				8,730
<u>Issuance of Ordinary Shares upon completion of public offering, net of offering expenses, shares</u>	[2] 5,376,472					
<u>Issuance of restricted shares as compensation towards directors</u>		5	(5)			
<u>Issuance of restricted shares as compensation towards directors, shares</u>	[2] 12,089					
<u>Stock-based compensation</u>		172				172
<u>Ending balance at Jun. 30, 2023</u>	\$ 20	\$ 112,913		\$ 28	\$ (105,218)	\$ 7,743
<u>Ending balance, shares at Jun. 30, 2023</u>		20,892,193				

[1] Actual issuance occurred subsequent to the balance sheet date.

[2] Represents amount lower than \$1.

**Condensed Consolidated  
Statements of Cash Flows  
(Unaudited) - USD (\$)  
\$ in Thousands**

**6 Months Ended  
Jun. 30, 2023 Jun. 30, 2022**

**CASH FLOWS FROM OPERATING ACTIVITIES**

Loss for the period \$ (2,462) \$ (2,220)

**Adjustments to reconcile net loss to net cash used in operating activities:**

Depreciation 7 14

Stock-based compensation 229 198

Issuance of restricted shares as compensation towards directors 5 20

Linkage difference on principal of loans from stockholders 6 6

**Changes in assets and liabilities:**

Increase in other current assets (104) (331)

Increase in accounts payable 173 18

Increase (Decrease) in other current liabilities (121) 114

Net cash used in operating activities (2,267) (2,181)

**CASH FLOWS FROM INVESTING ACTIVITIES:**

Purchase of property and equipment (4)

Net cash used in investing activities (4)

**CASH FLOWS FROM FINANCING ACTIVITIES:**

Net proceeds received from underwritten U.S. public offering 8,730

Net cash provided by financing activities 8,730

Effect of exchange rate changes on cash and cash equivalents, and restricted cash (10) (30)

Change in cash, cash equivalents, and restricted cash 6,453 (2,215)

Cash, cash equivalents, and restricted cash at beginning of the period 2,331 6,113

Cash, cash equivalents, and restricted cash, end of period 8,784 3,898

**Non-cash financing activities**

Deemed dividend upon trigger of down round protection \$ 855

## GENERAL

6 Months Ended  
Jun. 30, 2023

[Organization, Consolidation  
and Presentation of  
Financial Statements](#)

[\[Abstract\]](#)

[GENERAL](#)

### NOTE 1 – GENERAL

GlucoTrack Inc. (the “Company”) was incorporated on May 18, 2010 under the laws of the State of Delaware. The Company is a medical device company, focused on the design, development and commercialization of novel technologies for use by people with diabetes and prediabetes. The Company is currently developing two products; a non-invasive glucose monitor for use by persons with Type 2 diabetes and prediabetes, and an implantable continuous glucose monitor for persons with Type 1 diabetes and insulin-dependent Type 2 diabetes.

#### **B. Liquidity and Going Concern Uncertainty**

To date, the Company has not yet generated significant revenues from selling of GlucoTrack 1.0 product, a product that has been discontinued. In addition, development and commercialization of both GlucoTrack 2.0 product and the implantable continuous glucose monitor is expected to require substantial expenditures; therefore, the Company is dependent upon external sources for financing its operations. As of June 30, 2023, the Company has incurred accumulated deficit of \$105,218 thousand. Furthermore, the Company has generated operating losses and negative operating cash flow for all reported periods.

Management has considered the significance of such conditions in relation to the Company’s ability to meet its current obligations and to achieve its business targets and determined that these conditions do not raise substantial doubt about the Company’s ability to continue as a going concern, taking into consideration the net proceeds received in total amount of \$8,730 thousand upon closing of a public offering through prospectus supplement on Form S-3 on April 17 2023 (see also Note 3 below). Based on its assessment, management believe that such funds are sufficient for the Company to realize its business plans for the twelve months subsequent to the reporting period.

**SUMMARY OF  
SIGNIFICANT  
ACCOUNTING POLICIES**

**6 Months Ended**

**Jun. 30, 2023**

[Accounting Policies](#)

[\[Abstract\]](#)

[SUMMARY OF](#)

[SIGNIFICANT](#)

[ACCOUNTING POLICIES](#)

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**A. Basic of Presentation**

**1. Accounting Principles**

The accompanying unaudited condensed consolidated interim financial statements and related notes should be read in conjunction with the consolidated financial statements and related notes contained in the Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2023. The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature.

The results for the period of six months ended June 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other interim period or for any future period.

**2. Principles of Consolidation**

The consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany balances and transactions have been eliminated in consolidation.

**GLUCOTRACK INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(UNAUDITED)**

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)**

**A. Basic of Presentation**

**3. Net Loss Per Common Stock**

Basic net loss per Common Stock is computed by dividing the loss for the period applicable for holders of Common Stock and pre-funded warrants by the weighted average number of shares of Common Stock and pre-funded warrants outstanding during the period. Diluted loss per share gives effect to all potentially dilutive common shares outstanding during the period using the treasury stock method with respect to stock options and certain stock warrants. In computing diluted loss per Common Stock, the average stock price for the period is used in determining the number of Common Stock assumed to be purchased from the exercise of stock options or stock warrants.

Shares to be issued upon exercise of all stock options and stock warrants have been excluded from the calculation of the diluted net loss per Common Stock for all the reported periods for which net loss was reported because the effect of the Common Stock issuable upon exercise of these instruments was anti-dilutive.

The net loss and the weighted average number of shares of Common Stock used in computing basic and diluted net loss per Common Stock for the period of six and three months ended June 30, 2023 and 2022, is as follows:

	<u>US dollars (except share data)</u>		<u>US dollars (except share data)</u>	
	<u>Six-month period ended June 30,</u>		<u>Three-month period ended June 30,</u>	
	<u>(Unaudited)</u>		<u>(Unaudited)</u>	
	<u>2023</u>	<u>2022</u>	<u>2023</u>	<u>2022</u>
<b>Numerator:</b>				
Net loss	\$ 2,462	\$ 2,220	\$ 1,176	\$ 1,127
Deemed dividend related to trigger of down round protection feature (see Note 3A below)	855	-	855	-
Net loss attributable to common stockholders	\$ 3,317	\$ 2,220	\$ 2,031	\$ 1,127
<b>Denominator:</b>				
Ordinary shares used in computing basic and diluted net loss per common stock	(*)18,532,553	15,465,692	(*)21,561,473	15,473,813
Basic and diluted net loss per common stock	\$ (0.19)	\$ (0.14)	\$ (0.10)	\$ (0.07)

(\*) Including pre-funded warrants issued upon completion of underwritten U.S. public offering.

**GLUCOTRACK INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(UNAUDITED) (CONT.)**

**SIGNIFICANT  
TRANSACTIONS**

**6 Months Ended  
Jun. 30, 2023**

**Significant Transactions**  
**SIGNIFICANT**  
**TRANSACTIONS**

**NOTE 3 - SIGNIFICANT TRANSACTIONS**

**A. Completion of underwritten U.S. public offering**

On April 13, 2023, the Company completed an underwritten public offering under which the Company received gross proceeds of approximately \$10,000 thousand for issuance of (i) 5,376,472 shares of common stock and (ii) 1,976,470 pre-funded warrants at a price to the public of \$1.36 per share. The pre-funded warrants are exercisable for the same number of shares of common stock and may be exercised at any time until exercised in full at an exercise price of \$0.001.

Upon satisfaction of customary closing conditions, the closing date of the above underwritten public offering was April 17, 2023 (the "Closing Date").

The Company received substantially all the pre-funded warrant's proceeds upfront (without any conditions) as part of the pre-funded warrant's purchase price and in return the Company is obligated to issue fixed number of shares of common stock to the holders. Thus, pre-funded warrants were accounted for and were classified as additional paid-in capital as part of the Company's stockholders' equity.

Total incremental and direct issuance costs amounted to \$1,270 thousand. These expenses were deducted from additional paid-in capital as they were allocated to shares of Common Stock and pre-funded warrants.

Upon closing of underwritten U.S. public offering, a down round protection feature of certain warrants granted in previous years to service providers was triggered by the way of reduction of their exercise price from a price in a range of \$3.35-\$70.20 to a price of \$1.36 which represented the above public offering price. Such reduction was accounted for as deemed dividend estimated at total amount of \$855 thousand which was recorded as part of the additional paid-in capital versus increase of accumulated deficit. Regarding the effect of the loss per share, see also Note 2.A.3. above.

**B. Intellectual Property Purchase Agreement**

In the middle of June 2023, the Company achieved the first performance milestone out of the five performance milestones outlined in the Intellectual Property Purchase Agreement (the "Agreement") executed between the Company and Paul Goode, which is the Company's Chief Executive Officer (the "Seller") as October 7, 2022 (the "Closing Date"). As result, the Company is committed to issue 100,000 restricted shares to the Seller. During the periods of three and six months ended June 30, 2023, the Company recorded stock-based compensation expenses amounted to \$131 thousand which representing the quoted price of its Common Stock at the Closing Date, after taking into consideration a discount for lack of marketability in a rate of 30.4% over a restriction period of 1-year. As of June 30, 2023, achievement of all other performance milestones was not considered probable and thus no stock-based compensation expenses were recorded with respect to thereof.

**C. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard**

On May 26, 2023, the Company received a letter from Nasdaq that it no longer complies with Rule 5550(a)(2) of Nasdaq's Listing Rules (the "Rules") which require listed securities to maintain a minimum bid price of \$1 per share. However, the Rules provide the Company a compliance period of 180-days to regain compliance under which if

at any time during 180-days period the closing bid price of the Company's security is at least \$1 for a minimum of ten consecutive business days, Nasdaq will provide the Company written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance by the 180th day, the Company may be eligible for additional time to regain compliance or may face delisting.

## SUBSEQUENT EVENTS

**6 Months Ended  
Jun. 30, 2023**

[Subsequent Events](#)

[\[Abstract\]](#)

[SUBSEQUENT EVENTS](#)

### NOTE 4 - SUBSEQUENT EVENTS

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed interim consolidated financial statements were issued (August 14, 2023). Based upon this review, the Company did not identify any other subsequent events that would have required adjustment or disclosure in the financial statements.

**SUMMARY OF  
SIGNIFICANT  
ACCOUNTING POLICIES  
(Policies)**

**6 Months Ended**

**Jun. 30, 2023**

[Accounting Policies](#)

[\[Abstract\]](#)

[Basic of Presentation](#)

**A. Basic of Presentation**

**1. Accounting Principles**

The accompanying unaudited condensed consolidated interim financial statements and related notes should be read in conjunction with the consolidated financial statements and related notes contained in the Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2023. The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature.

The results for the period of six months ended June 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other interim period or for any future period.

**2. Principles of Consolidation**

The consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany balances and transactions have been eliminated in consolidation.

**GLUCOTRACK INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(UNAUDITED)**

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)**

**A. Basic of Presentation**

**3. Net Loss Per Common Stock**

Basic net loss per Common Stock is computed by dividing the loss for the period applicable for holders of Common Stock and pre-funded warrants by the weighted average number of shares of Common Stock and pre-funded warrants outstanding during the period. Diluted loss per share gives effect to all potentially dilutive common shares outstanding during the period using the treasury stock method with respect to stock options and certain stock warrants. In computing diluted loss per Common Stock, the average stock price for the period is used in determining the number of Common Stock assumed to be purchased from the exercise of stock options or stock warrants.

Shares to be issued upon exercise of all stock options and stock warrants have been excluded from the calculation of the diluted net loss per Common Stock for all the reported periods for which net loss was reported because the effect of the Common Stock issuable upon exercise of these instruments was anti-dilutive.

The net loss and the weighted average number of shares of Common Stock used in computing basic and diluted net loss per Common Stock for the period of six and three months ended June 30, 2023 and 2022, is as follows:

	<u>US dollars (except share data)</u>		<u>US dollars (except share data)</u>	
	<u>Six-month period ended June 30,</u>		<u>Three-month period ended June 30,</u>	
	<u>(Unaudited)</u>		<u>(Unaudited)</u>	
	<u>2023</u>	<u>2022</u>	<u>2023</u>	<u>2022</u>
<b>Numerator:</b>				
Net loss	\$ 2,462	\$ 2,220	\$ 1,176	\$ 1,127
Deemed dividend related to trigger of down round protection feature (see Note 3A below)	855	-	855	-
Net loss attributable to common stockholders	\$ 3,317	\$ 2,220	\$ 2,031	\$ 1,127
<b>Denominator:</b>				
Ordinary shares used in computing basic and diluted net loss per common stock	(*)18,532,553	15,465,692	(*)21,561,473	15,473,813
Basic and diluted net loss per common stock	\$ (0.19)	\$ (0.14)	\$ (0.10)	\$ (0.07)

(\*) Including pre-funded warrants issued upon completion of underwritten U.S. public offering.

**SUMMARY OF  
SIGNIFICANT  
ACCOUNTING POLICIES  
(Tables)**

[Accounting Policies \[Abstract\]](#)  
[SCHEDULE OF ANTIDILUTIVE  
NET LOSS AND WEIGHTED  
AVERAGE](#)

**6 Months Ended**

**Jun. 30, 2023**

US dollars (except share data)		US dollars (except share data)	
Six-month period ended June 30,		Three-month period ended June 30,	
(Unaudited)		(Unaudited)	
2023	2022	2023	2022

Numerator:								
Net loss	\$	2,462	\$	2,220	\$	1,176	\$	1,127
Deemed dividend related to trigger of down round protection feature (see Note 3A below)		855		-		855		-
Net loss attributable to common stockholders	\$	3,317	\$	2,220	\$	2,031	\$	1,127
Denominator:								
Ordinary shares used in computing basic and diluted net loss per common stock		(*)18,532,553		15,465,692		(*)21,561,473		15,473,813
Basic and diluted net loss per common stock	\$	(0.19)	\$	(0.14)	\$	(0.10)	\$	(0.07)

(\*) Including pre-funded warrants issued upon completion of underwritten U.S. public offering.

**GENERAL (Details  
Narrative) - USD (\$)  
\$ in Thousands**

**6 Months  
Ended  
Jun. 30, 2023      Dec. 31,  
2022**

**Organization, Consolidation and Presentation of Financial Statements**

**[Abstract]**

Accumulated deficit

\$ 105,218

\$ 101,901

Net proceeds

\$ 8,730

**SCHEDULE OF  
ANTIDILUTIVE NET  
LOSS AND WEIGHTED  
AVERAGE (Details) - USD  
(\$)  
\$ / shares in Units, \$ in  
Thousands**

	<b>3 Months Ended</b>		<b>6 Months Ended</b>	
	<b>Jun. 30, 2023</b>	<b>Jun. 30, 2022</b>	<b>Jun. 30, 2023</b>	<b>Jun. 30, 2022</b>
<a href="#">Net loss</a>	\$ 1,176	\$ 1,127	\$ 2,462	\$ 2,220
<a href="#">Deemed dividend related to trigger of down round protection feature (see Note 3A below)</a>	855		855	
<a href="#">Net basic loss</a>	2,031	1,127	3,317	2,220
<a href="#">Net diluted loss</a>	\$ 2,031	\$ 1,127	\$ 3,317	\$ 2,220
<a href="#">Ordinary shares used in computing basic net loss per common stock</a>	21,561,473	15,473,813	18,532,553	15,465,692
<a href="#">Ordinary shares used in computing diluted net loss per common stock</a>	21,561,473	15,473,813	18,532,553	15,465,692
<a href="#">Basic net loss per common stock</a>	\$ (0.09)	\$ (0.07)	\$ (0.18)	\$ (0.14)
<a href="#">Diluted net loss per common stock</a>	\$ (0.09)	\$ (0.07)	\$ (0.18)	\$ (0.14)
<a href="#">Prefunded Warrants [Member]</a>				
<a href="#">Ordinary shares used in computing basic net loss per common stock</a>	[1] 21,561,473		18,532,553	
<a href="#">Ordinary shares used in computing diluted net loss per common stock</a>	[1] 21,561,473		18,532,553	
<a href="#">Basic net loss per common stock</a>	\$ (0.10)		\$ (0.19)	
<a href="#">Diluted net loss per common stock</a>	\$ (0.10)		\$ (0.19)	

[1] Including pre-funded warrants issued upon completion of underwritten U.S. public offering.

**SIGNIFICANT  
TRANSACTIONS (Details  
Narrative) - USD (\$)  
\$ / shares in Units, \$ in  
Thousands**

**6  
Months  
Ended  
Apr. 13, Jun. May  
2023 30, 26,  
2023 2023**

**Apr. 13, 2023**

<u>Description of common stock</u>	the Company received gross proceeds of approximately \$10,000 thousand for issuance of (i) 5,376,472 shares of common stock and (ii) 1,976,470 pre-funded warrants at a price to the public of \$1.36 per share. The pre-funded warrants are exercisable for the same number of shares of common stock and may be exercised at any time until exercised in full at an exercise price of \$0.001			
<u>Gross proceeds</u>	\$ 10,000			
<u>Exercise price</u>	\$ 1.36	\$ 1.36		
<u>Incremental and direct issuance costs</u>	\$ 1,270			
<u>Additional paid in capital</u>	\$ 855	\$ 855		
<u>Minimum bid price</u>				\$ 1
<u>Intellectual Property Purchase Agreement [Member]</u>				
<u>Number of common shares issued</u>				100,000
<u>Share based compensation</u>				\$ 131
<u>Discount rate</u>				30.40%
<u>Minimum [Member]</u>				
<u>Exercise price</u>	\$ 3.35	\$ 3.35		
<u>Maximum [Member]</u>				
<u>Exercise price</u>	70.20	\$ 70.20		
<u>Common Stock [Member]</u>				
<u>Number of common shares issued</u>				5,376,472
<u>Exercise price</u>	0.001	\$ 0.001		
<u>Prefunded Warrants [Member]</u>				
<u>Number of common shares issued</u>				1,976,470
<u>Share price</u>	1.36	\$ 1.36		
<u>Exercise price</u>	\$ 0.001	\$ 0.001		



1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the sampling process and the statistical techniques employed to ensure the reliability of the results.

3. The third part of the document presents the findings of the study. It highlights the key trends and patterns observed in the data, as well as the implications of these findings for the industry and the broader economy.

4. The fourth part of the document discusses the limitations of the study and the potential areas for future research. It acknowledges the challenges faced during the data collection process and offers suggestions for improving the quality of the data.

5. The fifth part of the document provides a conclusion and a summary of the main points. It reiterates the importance of accurate record-keeping and the need for ongoing monitoring and evaluation of the data.

6. The sixth part of the document includes a list of references and a bibliography. It cites the various sources used in the study, including academic journals, books, and industry reports.

7. The seventh part of the document contains a list of appendices and a glossary. It provides additional information and definitions for the terms used in the document.

8. The eighth part of the document includes a list of figures and tables. It provides a visual representation of the data and a summary of the key findings.

9. The ninth part of the document contains a list of footnotes and a list of abbreviations. It provides additional information and clarifications for the terms used in the document.

10. The tenth part of the document includes a list of acknowledgments and a list of contributors. It expresses gratitude to the individuals and organizations that supported the study.

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the sampling process and the statistical techniques employed to ensure the reliability of the results.

3. The third part of the document presents the findings of the study. It provides a comprehensive overview of the data collected and the conclusions drawn from the analysis. The results indicate that there is a significant correlation between the variables studied.

4. The fourth part of the document discusses the implications of the findings and offers recommendations for future research. It suggests that further studies should be conducted to explore the underlying causes of the observed trends and to develop effective strategies to address them.

5. The fifth part of the document provides a summary of the key points discussed throughout the report. It reiterates the importance of accurate record-keeping and the need for ongoing monitoring and evaluation of the system.

6. The sixth part of the document includes a list of references and a bibliography. It cites the various sources of information used in the study, including academic journals, books, and industry reports.

7. The seventh part of the document contains a list of appendices and supplementary materials. These include detailed data tables, charts, and graphs that provide additional context and support for the findings presented in the main text.

8. The eighth part of the document provides a list of contact information for the authors and the research team. It includes email addresses and phone numbers for those who wish to request further information or discuss the study in more detail.

9. The ninth part of the document includes a list of acknowledgments and a thank-you note. It expresses appreciation to the individuals and organizations that provided support and assistance throughout the course of the research.

10. The tenth part of the document contains a list of footnotes and a glossary of terms. It provides definitions for key concepts and clarifies any potential ambiguities in the text.

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the sampling process and the statistical techniques employed to ensure the reliability of the results.

3. The third part of the document presents the findings of the study. It shows that there is a significant correlation between the variables being studied, and that the results are consistent across different groups and time periods.

4. The fourth part of the document discusses the implications of the findings and offers suggestions for further research. It highlights the need for continued monitoring and evaluation of the system to ensure its effectiveness and efficiency.

5. The fifth part of the document provides a summary of the key points and conclusions. It reiterates the importance of the findings and the need for continued attention to the issues discussed.

6. The sixth part of the document includes a list of references and a bibliography. It cites the various sources used in the study and provides information on how to access them.

7. The seventh part of the document contains a list of appendices and a table of contents. It provides a detailed overview of the document's structure and the location of each section.

8. The eighth part of the document includes a list of figures and tables. It provides a detailed description of each figure and table and explains how they relate to the findings of the study.

9. The ninth part of the document contains a list of footnotes and a glossary. It provides additional information on the various terms and concepts used in the document and explains their meaning.

10. The tenth part of the document includes a list of acknowledgments and a list of authors. It expresses gratitude to the individuals and organizations that supported the study and provides information on the authors' contact information.

Item	Quantity	Unit	Price	Total
1. Cement	1000	kg	1.20	1200.00
2. Sand	2000	kg	0.80	1600.00
3. Gravel	1500	kg	1.50	2250.00
4. Steel Reinforcement	500	kg	2.50	1250.00
5. Labor	100	hr	15.00	1500.00
6. Formwork	100	sqm	10.00	1000.00
7. Water	500	liters	0.20	100.00
8. Electricity	100	hr	10.00	1000.00
9. Transportation	100	hr	10.00	1000.00
10. Safety Equipment	100	hr	10.00	1000.00
11. Miscellaneous	100	hr	10.00	1000.00
12. Contingency	100	hr	10.00	1000.00
13. Profit	100	hr	10.00	1000.00
14. Tax	100	hr	10.00	1000.00
15. Insurance	100	hr	10.00	1000.00
16. Maintenance	100	hr	10.00	1000.00
17. Training	100	hr	10.00	1000.00
18. Research	100	hr	10.00	1000.00
19. Development	100	hr	10.00	1000.00
20. Testing	100	hr	10.00	1000.00
21. Deployment	100	hr	10.00	1000.00
22. Support	100	hr	10.00	1000.00
23. Documentation	100	hr	10.00	1000.00
24. Marketing	100	hr	10.00	1000.00
25. Sales	100	hr	10.00	1000.00
26. Customer Service	100	hr	10.00	1000.00
27. HR	100	hr	10.00	1000.00
28. Finance	100	hr	10.00	1000.00
29. Legal	100	hr	10.00	1000.00
30. Compliance	100	hr	10.00	1000.00
31. Security	100	hr	10.00	1000.00
32. Risk Management	100	hr	10.00	1000.00
33. Quality Assurance	100	hr	10.00	1000.00
34. Project Management	100	hr	10.00	1000.00
35. Communication	100	hr	10.00	1000.00
36. Collaboration	100	hr	10.00	1000.00
37. Innovation	100	hr	10.00	1000.00
38. Creativity	100	hr	10.00	1000.00
39. Problem Solving	100	hr	10.00	1000.00
40. Decision Making	100	hr	10.00	1000.00
41. Leadership	100	hr	10.00	1000.00
42. Teamwork	100	hr	10.00	1000.00
43. Accountability	100	hr	10.00	1000.00
44. Integrity	100	hr	10.00	1000.00
45. Honesty	100	hr	10.00	1000.00
46. Transparency	100	hr	10.00	1000.00
47. Openness	100	hr	10.00	1000.00
48. Communication	100	hr	10.00	1000.00
49. Collaboration	100	hr	10.00	1000.00
50. Innovation	100	hr	10.00	1000.00
51. Creativity	100	hr	10.00	1000.00
52. Problem Solving	100	hr	10.00	1000.00
53. Decision Making	100	hr	10.00	1000.00
54. Leadership	100	hr	10.00	1000.00
55. Teamwork	100	hr	10.00	1000.00
56. Accountability	100	hr	10.00	1000.00
57. Integrity	100	hr	10.00	1000.00
58. Honesty	100	hr	10.00	1000.00
59. Transparency	100	hr	10.00	1000.00
60. Openness	100	hr	10.00	1000.00
61. Communication	100	hr	10.00	1000.00
62. Collaboration	100	hr	10.00	1000.00
63. Innovation	100	hr	10.00	1000.00
64. Creativity	100	hr	10.00	1000.00
65. Problem Solving	100	hr	10.00	1000.00
66. Decision Making	100	hr	10.00	1000.00
67. Leadership	100	hr	10.00	1000.00
68. Teamwork	100	hr	10.00	1000.00
69. Accountability	100	hr	10.00	1000.00
70. Integrity	100	hr	10.00	1000.00
71. Honesty	100	hr	10.00	1000.00
72. Transparency	100	hr	10.00	1000.00
73. Openness	100	hr	10.00	1000.00
74. Communication	100	hr	10.00	1000.00
75. Collaboration	100	hr	10.00	1000.00
76. Innovation	100	hr	10.00	1000.00
77. Creativity	100	hr	10.00	1000.00
78. Problem Solving	100	hr	10.00	1000.00
79. Decision Making	100	hr	10.00	1000.00
80. Leadership	100	hr	10.00	1000.00
81. Teamwork	100	hr	10.00	1000.00
82. Accountability	100	hr	10.00	1000.00
83. Integrity	100	hr	10.00	1000.00
84. Honesty	100	hr	10.00	1000.00
85. Transparency	100	hr	10.00	1000.00
86. Openness	100	hr	10.00	1000.00
87. Communication	100	hr	10.00	1000.00
88. Collaboration	100	hr	10.00	1000.00
89. Innovation	100	hr	10.00	1000.00
90. Creativity	100	hr	10.00	1000.00
91. Problem Solving	100	hr	10.00	1000.00
92. Decision Making	100	hr	10.00	1000.00
93. Leadership	100	hr	10.00	1000.00
94. Teamwork	100	hr	10.00	1000.00
95. Accountability	100	hr	10.00	1000.00
96. Integrity	100	hr	10.00	1000.00
97. Honesty	100	hr	10.00	1000.00
98. Transparency	100	hr	10.00	1000.00
99. Openness	100	hr	10.00	1000.00
100. Communication	100	hr	10.00	1000.00

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the sampling process and the statistical techniques employed to ensure the reliability of the results.

3. The third part of the document presents the findings of the study. It shows that there is a significant correlation between the variables being studied, and that the results are consistent across different groups and time periods.

4. The fourth part of the document discusses the implications of the findings and offers suggestions for further research. It highlights the need for continued monitoring and evaluation of the system to ensure its effectiveness and efficiency.

5. The fifth part of the document provides a summary of the key points and conclusions. It reiterates the importance of accurate record-keeping and the need for ongoing research and improvement in the field.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the sampling process and the statistical techniques employed to interpret the results.

3. The third part of the document presents the findings of the study. It shows that there is a significant correlation between the variables being studied, and it provides a clear explanation of the underlying reasons for this relationship.

4. The fourth part of the document discusses the implications of the findings for future research and practice. It suggests that the results of this study could be used to inform policy decisions and to guide the development of new programs and initiatives.

5. The fifth part of the document concludes the study and provides a final summary of the key findings. It reiterates the importance of the research and the need for continued efforts to improve the quality of data collection and analysis.

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the sampling process and the statistical techniques employed to interpret the results.

3. The third part of the document presents the findings of the study. It provides a comprehensive overview of the data collected and the conclusions drawn from the analysis.

4. The fourth part of the document discusses the implications of the findings and offers recommendations for future research. It highlights the need for further investigation into the areas identified as significant in the study.

5. The fifth part of the document provides a summary of the key points discussed throughout the document. It serves as a concise overview of the entire report.

6. The sixth part of the document contains the references and bibliography. It lists all the sources used in the research, providing a clear path for readers to access the original materials.

7. The seventh part of the document includes the appendices. These sections provide additional information and data that support the main findings of the study.

8. The eighth part of the document contains the index. It provides a quick reference to the various sections and topics covered in the document.

9. The ninth part of the document includes the glossary. It defines the key terms and concepts used throughout the report, ensuring clarity and consistency in the language.

10. The tenth part of the document contains the conclusion. It summarizes the overall findings and provides a final statement on the significance of the research.

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods and techniques used to collect and analyze data. It includes a detailed description of the experimental procedures and the statistical tools employed.

3. The third part of the document presents the results of the study, showing the trends and patterns observed in the data. It includes several tables and graphs to illustrate the findings.

4. The fourth part of the document discusses the implications of the results and the potential applications of the findings. It highlights the significance of the study and the need for further research in this area.

5. The fifth part of the document provides a conclusion and a summary of the key points discussed throughout the document. It also includes a list of references and a bibliography.





1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the sampling process and the statistical techniques employed to ensure the reliability of the results.

3. The third part of the document presents the findings of the study. It shows that there is a significant correlation between the variables being studied, and that the results are consistent across different groups and time periods.

4. The fourth part of the document discusses the implications of the findings and provides recommendations for future research. It suggests that further studies should be conducted to explore the underlying causes of the observed trends and to develop effective strategies to address them.

5. The fifth part of the document concludes the study and summarizes the key points. It reiterates the importance of accurate record-keeping and the need for ongoing monitoring and evaluation of the system.

1. The first step in the process of...  
2. The second step is to...  
3. The third step involves...  
4. The fourth step is to...  
5. The fifth step is to...  
6. The sixth step is to...  
7. The seventh step is to...  
8. The eighth step is to...  
9. The ninth step is to...  
10. The tenth step is to...  
11. The eleventh step is to...  
12. The twelfth step is to...  
13. The thirteenth step is to...  
14. The fourteenth step is to...  
15. The fifteenth step is to...  
16. The sixteenth step is to...  
17. The seventeenth step is to...  
18. The eighteenth step is to...  
19. The nineteenth step is to...  
20. The twentieth step is to...  
21. The twenty-first step is to...  
22. The twenty-second step is to...  
23. The twenty-third step is to...  
24. The twenty-fourth step is to...  
25. The twenty-fifth step is to...  
26. The twenty-sixth step is to...  
27. The twenty-seventh step is to...  
28. The twenty-eighth step is to...  
29. The twenty-ninth step is to...  
30. The thirtieth step is to...  
31. The thirty-first step is to...  
32. The thirty-second step is to...  
33. The thirty-third step is to...  
34. The thirty-fourth step is to...  
35. The thirty-fifth step is to...  
36. The thirty-sixth step is to...  
37. The thirty-seventh step is to...  
38. The thirty-eighth step is to...  
39. The thirty-ninth step is to...  
40. The fortieth step is to...  
41. The forty-first step is to...  
42. The forty-second step is to...  
43. The forty-third step is to...  
44. The forty-fourth step is to...  
45. The forty-fifth step is to...  
46. The forty-sixth step is to...  
47. The forty-seventh step is to...  
48. The forty-eighth step is to...  
49. The forty-ninth step is to...  
50. The fiftieth step is to...

Page 1 of 1  
Date: 10/10/2019  
Time: 10:10:10  
User: Administrator  
IP: 192.168.1.1  
Browser: Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/78.0.3930.88 Safari/537.36  
URL: http://192.168.1.1/